Device Trial Radar · NCT05255991
Multinational Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis
Last checked: Nov 20, 2026Latest source record: Oct 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
597
Actual
Start
Sep 12, 2022
Primary completion
Jun 30, 2025
Study completion Jun 30, 2025
Sponsor
- Lead sponsor
- United TherapeuticsNot on our public-company list
- Sponsor type
- Industry
- First posted
- Feb 25, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Study RIN-PF-303 is a multinational study designed to evaluate the superiority of inhaled treprostinil against placebo for the change in absolute forced vital capacity (FVC) from baseline to Week 52.
Conditions
- Idiopathic Pulmonary Fibrosis
- Interstitial Lung Disease
Interventions
PlaceboDrug
Placebo administered QID
Inhaled TreprostinilDrug
Inhaled treprostinil (6 mcg/breath) administered QID
Treprostinil Ultrasonic NebulizerDevice
Treprostinil ultrasonic nebulizer which emits a dose of approximately 6 mcg per breath.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Absolute FVC From Baseline to Week 52Time frame: Baseline to Week 52
Locations
108 sites in 16 countries. Site status is shown where the registry gives one.
CINME S.A. - Centro de Investigaciones Metabolicas
Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina
Centro Medico Dra. De Salvo
Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina
Instituto Ave Pulmo - Fundación enfisema
Mar del Plata, Buenos Aires, Argentina
105 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.